Key Highlights

• $929 Million All-Cash Acquisition: The deal adds YUPELRI, the only approved nebulized LAMA for COPD, with approximately $60 million in annualized cash flow.

• Strong 2025 Net Sales Growth: YUPELRI generated 2025 US net sales of $266.6 million, up 12% year-over-year.

• Multiple Analyst Price Target Increases: Wells Fargo raised its target to $37, Stifel reiterated Buy at $47, and H.C. Wainwright maintained Buy at $46.

Zymeworks (NASDAQ: ZYME) surged 10% as investors warmed to its $929 million all-cash acquisition of Theravance Biopharma, announced June 29, adding YUPELRI — the only approved nebulized LAMA for COPD — to its commercial portfolio.

The acquired asset brings approximately $60 million in annualized cash flow and 2025 US net sales of $266.6 million, up 12% year-over-year, providing Zymeworks with an immediately accretive, revenue-generating commercial product to complement its existing pipeline.

Analyst conviction is building rapidly around the deal: Wells Fargo raised its price target to $37 with an Overweight rating, Stifel reiterated Buy at $47, and H.C. Wainwright maintained Buy at $46, reflecting broad-based positive sentiment across multiple research firms.

The deal's non-dilutive financing structure and expected earnings accretion appear to be winning over the market a day after the initial announcement, as investors digest the strategic and financial logic behind the transaction more fully.

By acquiring an already-approved, revenue-generating respiratory drug, Zymeworks is diversifying its business model beyond pure pipeline-stage biotech risk, adding a layer of commercial revenue stability that analysts appear to be rewarding with improved price targets.

()